Innovative back microsurgery

Press release

VEXIM Opens U.S. Subsidiary

Office to support VEXIM's product portfolio launch in the U.S.

Toulouse, September 8, 2014 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced it has created the VEXIM Inc. legal entity that will serve as the Company's U.S. subsidiary for marketing VEXIM's product portfolio in the U.S. It will support VEXIM's planned commercial launch in early 2015 of vertebroplasty and kyphoplasty solutions to serve the $500M vertebral augmentation market.

VEXIM will approach the U.S. market through a select network of agents and dealers and will be appointing a world-class team of senior sales and marketing professionals to lead and implement this project.

Vincent Gardès, CEO of VEXIM, commented: *"We are pleased to have made such substantial progress to be in the position of readying the Company for an opening of our U.S. operations. Our plan is to develop a U.S.-based scientific and business team that can advance the understanding of the benefits of products that better treat vertebral compression fractures. Simultaneously, we are initiating U.S. approval process of SpineJack®, our unique implant designed to repair fractured vertebra and restore anatomical balance to the spinal column, with the goal of bringing SpineJack® to the U.S. as well."*

***

Next Communication:

First Half 2014 Financial results: September 29, 2014*

*indicative date

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital[1] and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 57 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama and in the following countries where the product is currently being registered: Mexico, Brazil, Venezuela, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3, 2012.
For further information, please go to www.vexim.com

SpineJack®[2] revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Specialized instruments and guided by X-ray allow the implants into the vertebra to be carried out by mini-invasive surgery in approximately 30 minutes enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of three titanium implants with three different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

Contacts

VEXIM
Vincent Gardès
CEO
Tel: +33 5 61 48 48 38
shareholders@vexim.com

NewCap
Investor Relations / Strategic Communications
Dusan Oresansky / Emmanuel Huynh
Tel: +33 1 44 71 94 92
vexim@newcap.fr

Alize RP
Press Relations
Caroline Carmagnol/Laure-Line Heim
vexim@alizerp.com
Tel: +33 1 70 22 53 86 / +33 6 64 18 99 59

LifeSci Advisors LLC
Investor Relations
Michael Wood
www.lifesciadvisors.com
+1 646 597 6983

ALVXM LISTED NYSE ALTERNEXT

- **Name:** VEXIM
- **ISIN code:** FR0011072602
- **Ticker:** ALVXM

ELIGIBLE PEA PME

[1] Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

[2] This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.